New Pfizer and BioNTech Research for Omicron Vaccine Begins

Science

Pfizer and BioNTech have begun a new trial for an Omicron vaccine that will test several factors such as safety, efficacy and endurability in people 18 to 55 years of age. The trial will involve over 1400 participants who are in good health, and who will be divided into three sets.

One group has had 2 prior doses and will receive 1 or 2 rounds of the new Omicron vaccine, the next has had all 3 doses of the current vaccine and will receive 1 of the Omicron, the third is for those who have not received any of the current vaccines, and they will get three of the Omicron one.

“The trial will involve over 1400 participants who are in good health, and who will be divided into three sets“

Head of vaccine R&D at Pfizer, Kathrin Jansen, explained that “while current research and real-world data show that boosters continue to provide a high level of protection, we recognise the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future.”

CEO of BioNTech, Professor Ugur Sahin, commented that: “Vaccines continue to offer strong protection against severe disease caused by Omicron. Yet, emerging data indicate vaccine-induced protection against infection and mild to moderate disease wanes more rapidly than was observed with prior strains. This study is part of our science-based approach to develop a variant-based vaccine that achieves a similar level of protection against Omicron as it did with earlier variants but with longer duration of protection.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

See all the latest jobs in Science
Return to news